Baker BROS. Advisors LP Purchases 455,208 Shares of GRAIL, Inc. $GRAL

Baker BROS. Advisors LP grew its position in GRAIL, Inc. (NASDAQ:GRAL) by 27.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,085,333 shares of the company’s stock after purchasing an additional 455,208 shares during the quarter. GRAIL makes up about 1.0% of Baker BROS. Advisors LP’s investment portfolio, making the stock its 14th largest holding. Baker BROS. Advisors LP owned approximately 0.05% of GRAIL worth $178,484,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. N.E.W. Advisory Services LLC bought a new position in shares of GRAIL in the fourth quarter worth approximately $26,000. Comerica Bank boosted its position in shares of GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares during the period. Elyxium Wealth LLC bought a new position in shares of GRAIL in the fourth quarter worth approximately $31,000. Intesa Sanpaolo S.p.A. bought a new position in shares of GRAIL in the fourth quarter worth approximately $44,000. Finally, Ankerstar Wealth LLC bought a new position in shares of GRAIL in the fourth quarter worth approximately $45,000.

Analyst Ratings Changes

Several equities analysts have recently commented on GRAL shares. Guggenheim lowered their target price on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Robert W. Baird set a $70.00 target price on shares of GRAIL in a report on Wednesday, May 6th. Wolfe Research started coverage on shares of GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Tuesday, April 21st. Finally, TD Cowen boosted their target price on shares of GRAIL from $65.00 to $69.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $67.00.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: The stock is getting active trading interest as multiple law firms publicized the August 4, 2026 lead-plaintiff deadline, keeping GRAIL in the spotlight and drawing attention from investors following the sharp prior selloff. Article Title
• Neutral Sentiment: Several firms, including Levi & Korsinsky, Bernstein Liebhard, Rosen, Schall, Pomerantz, Faruqi & Faruqi, Glancy Prongay, and others, reiterated that a securities class action has been filed and that investors who bought shares during the May 13, 2025 to February 19, 2026 period may seek lead-plaintiff status. Article Title
• Negative Sentiment: The underlying allegation remains that GRAIL allegedly withheld detailed NHS-Galleri trial data and misled investors, which could raise legal risk, pressuring sentiment even though no operational update was reported. Article Title

GRAIL Stock Performance

GRAL stock opened at $59.45 on Thursday. GRAIL, Inc. has a one year low of $29.95 and a one year high of $118.84. The company’s fifty day moving average price is $58.55 and its 200-day moving average price is $73.24. The company has a market capitalization of $2.55 billion, a PE ratio of -5.73 and a beta of 3.15.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. The company had revenue of $40.79 million for the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. On average, research analysts predict that GRAIL, Inc. will post -10.99 EPS for the current fiscal year.

Insider Buying and Selling at GRAIL

In related news, CFO Aaron Freidin sold 45,806 shares of the company’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the sale, the chief financial officer owned 260,669 shares of the company’s stock, valued at $13,012,596.48. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Joshua J. Ofman sold 61,665 shares of the company’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the sale, the president directly owned 371,216 shares in the company, valued at approximately $18,531,102.72. The trade was a 14.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 232,464 shares of company stock worth $11,621,242 in the last ninety days. Company insiders own 1.83% of the company’s stock.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.